Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D; CLSI Subcommittee for Antifungal Susceptibility Testing.

Drug Resist Updat. 2010 Dec;13(6):180-95. doi: 10.1016/j.drup.2010.09.002. Epub 2010 Nov 2. Review.

PMID:
21050800
2.

Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent.

Staab JF, Kahn JN, Marr KA.

Antimicrob Agents Chemother. 2010 Dec;54(12):4992-8. doi: 10.1128/AAC.00774-10. Epub 2010 Sep 20.

3.
4.

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG.

Clin Infect Dis. 2010 Apr 15;50(8):1091-100. doi: 10.1086/651263.

PMID:
20218877
5.

Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM.

Clin Infect Dis. 2010 Apr 15;50(8):1101-11. doi: 10.1086/651262.

PMID:
20218876
6.

Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

Diagn Microbiol Infect Dis. 2010 May;67(1):56-60. doi: 10.1016/j.diagmicrobio.2010.01.001. Epub 2010 Mar 5.

PMID:
20207095
7.

The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.

Cuenca-Estrella M, Rodriguez-Tudela JL.

Expert Rev Anti Infect Ther. 2010 Mar;8(3):267-76. doi: 10.1586/eri.10.2. Review.

PMID:
20192681
8.

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ.

J Clin Microbiol. 2009 Oct;47(10):3323-5. doi: 10.1128/JCM.01155-09. Epub 2009 Aug 26.

9.

Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network.

Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA.

J Clin Microbiol. 2009 Oct;47(10):3271-5. doi: 10.1128/JCM.00854-09. Epub 2009 Aug 19.

10.

Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network.

Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, Andes D, Kontoyiannis DP, Perrone G, Peterson S, Brandt ME, Pappas PG, Chiller T.

J Clin Microbiol. 2009 Oct;47(10):3138-41. doi: 10.1128/JCM.01070-09. Epub 2009 Aug 12.

11.

In vitro activity of nine antifungal agents against clinical isolates of Aspergillus calidoustus.

Alastruey-Izquierdo A, Cuesta I, Houbraken J, Cuenca-Estrella M, Monzón A, Rodriguez-Tudela JL.

Med Mycol. 2010 Feb;48(1):97-102. doi: 10.3109/13693780902803040.

PMID:
19296366
12.

Aspergillus section Fumigati: antifungal susceptibility patterns and sequence-based identification.

Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Cuenca-Estrella M, Rodriguez-Tudela JL.

Antimicrob Agents Chemother. 2008 Apr;52(4):1244-51. doi: 10.1128/AAC.00942-07. Epub 2008 Jan 22.

13.

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, van Burik JA, Wingard JR, Patterson TF; Infectious Diseases Society of America.

Clin Infect Dis. 2008 Feb 1;46(3):327-60. doi: 10.1086/525258. No abstract available.

PMID:
18177225
14.

Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.

Madureira A, Bergeron A, Lacroix C, Robin M, Rocha V, de Latour RP, Ferry C, Devergie A, Lapalu J, Gluckmana E, Socié G, Ghannoum M, Ribaud P.

Int J Antimicrob Agents. 2007 Dec;30(6):551-4.

PMID:
18029149
15.

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.

Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ.

Antimicrob Agents Chemother. 2008 Jan;52(1):321-8. Epub 2007 Oct 15.

16.

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases.

Clin Infect Dis. 2002 Jan 1;34(1):7-14. Epub 2001 Nov 26.

PMID:
11731939

Supplemental Content

Support Center